

RECEIVED

SEP 23 2002

TECH CENTER 1600/2900



D-2939CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In the application of:

WILLIAMS ET AL

Serial No. 08/704,159

Filed: August 28, 1996

For: SOLUBLE RECOMBINANT BOTULINUM
TOXIN PROTEINS

Group Art Unit: 1648

Examiner: Bao Qun Li

I hereby certify that this correspondence is being
deposited with the United States Postal Service
with sufficient postage as first class mail in
an envelope addressed to: Commissioner
for Patents, Washington, DC 20231, on or before

SEPTEMBER 13, 2002
Frank J. Uxa
Title Attorney
Date 9/13/02

LETTER TRANSMITTING TERMINAL DISCLAIMER

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Submitted herewith is a Terminal Disclaimer in the above-identified application. In addition, authorization is hereby given to charge Deposit Account No. 01-0885 in the amount of \$110.00 (37 CFR 1.20(d)) to cover the required fee. Duplicate copies of this letter are enclosed.

Respectfully submitted,

Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

FJUxa/jm



D-2939CIP

2

RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In the application of:

WILLIAMS ET AL

Serial No. 08/704,159

Filed: August 28, 1996

For: SOLUBLE RECOMBINANT BOTULINUM
TOXIN PROTEINS

Group Art Unit: 1648

Examiner: Bao Qun Li

I hereby certify that this correspondence is being
deposited with the United States Postal Service
with sufficient postage as first class mail in
an envelope addressed to: Commissioner
for Patents, Washington, DC 20231, on or before

Title

Date

TERMINAL DISCLAIMER

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Your petitioner, Allergan, Inc., having its principal place of
business at 2525 Dupont Drive, Irvine, CA 92612, by its attorney,
FRANK J. UXA, of record in the above-identified application,
represents that it is the assignee, as shown by the assignment
recorded in the U.S. Patent and Trademark Office September 26, 2000
at Real/Frame 011183/0764 and 011177/0325 of the entire right,
title and interest in and to the above-identified application.

D-2939CIP

Pursuant to 37 CFR 3.73(b), your petitioner, as assignee of the above-identified application, hereby states that the above-noted assignment, the evidentiary document on which ownership of the above-identified application is established, has been reviewed. Further, your petitioner hereby certifies that, to the best of your petitioner's knowledge and belief, title to the above-identified application is in your petitioner, as assignee seeking to take the action in this Terminal Disclaimer.

Your petitioner, Allergan, Inc., hereby disclaims the terminal part of any United States patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of **U.S. Patent 5,919,665** and hereby agrees that any United States patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to **U.S. Patent 5,919,665** this agreement to run with any patent granted on the above-identified application and be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of **U.S. Patent 5,919,665** in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated

D-2939CIP

prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Dated this 13th day of SEPTEMBER, 2002.

Respectfully submitted,



FRANK J. UXA, Attorney of Record
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile: (949) 450-1764

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Williams et al

Docket No.

D-2939CIP


Serial No.
08/704,159

Filing Date
08/28/1996

Examiner
Bao Qun Li

Group Art Unit
1648

Invention: SOLUBLE RECOMBINANT BOTULINUM TOXIN PROTEINS



TECH CENTER 1600/2900

SEP 23 2002

RECEIVED

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	-	68 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	-	9 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- ☐ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. 01-0885 in the amount of
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-0885
A duplicate copy of this sheet is enclosed.
 - ☒ Any additional filing fees required under 37 C.F.R. 1.16.
 - ☒ Any patent application processing fees under 37 CFR 1.17.

Frank J. Uxa
Signature

Dated:

9/13/02

Frank J. Uxa
Attorney For Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618

I certify that this document and fee is being deposited on 9/13/02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Frank J. Uxa
Signature of Person Mailing Correspondence

FRANK J. UXIA

Typed or Printed Name of Person Mailing Correspondence

cc: